<--GAT-->

ASCO Reporter



More for You

ASCO Reporter

Therapy Combinations Were Safe, Active in Genitourinary Cancer Trials

Federal researchers reported updated results of trials of cabozantinib plus nivolumab with and without ipilimumab in patients with refractory metastatic urothelial carcinoma on Saturday at the 2018 American Society of Clinical Oncology Annual Meeting.

ASCO Reporter

Cabozantinib Improves Survival in Liver Cancer Regardless of Age

HOUSTON — For veterans with hepatocellular carcinoma (HCC), research presented today at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago offers encouraging the news. The study determined that a new tyrosine kinase... View Article

ASCO Reporter

Pulmonary Events Affect 30% of Hodgkin Lymphoma Patients Post-Chemo

Bleomycin, the first line standard of care for Hodgkin lymphoma causes pulmonary events in some patients, but physicians have been uncertain how many patients are affected and how long they remain at risk.

ASCO Reporter

VA Team Develops Reliable Measure of Cancer Drug Efficacy

Assessing tumor growth and regression to determine a treatment’s efficacy over time can be challenging on an individual basis.

ASCO Reporter

Common Vitamin Deficiency Increases Mortality Risk 80% in Cancer Patients

Vitamin D deficiency doesn’t just increase the risk of osteoporosis and other bone disorders, it dramatically increases the risk of death in older cancer patients with solid tumors, according to researchers at the Central Texas Veterans Healthcare System in Temple, and the University of Texas MD Anderson Cancer Center in Houston.

ASCO Reporter

Risk Predictor Guides Breast Cancer Treatment at MHS Facility

Physicians and patients want to do everything possible to minimize the risk of breast cancer recurrence without incurring unnecessary toxicity from chemotherapy.

ASCO Reporter

Test Accurately Predicts Overall Survival in Prostate Cancer

For the physicians treating men with non-metastatic castration resistant prostate cancer, knowing the risk of progression or death provides valuable information to guide the timing and selection of treatment.